LBA35 Phase II study of PARP inhibitor talazoparib and PD-L1 inhibitor avelumab in patients (pts) with microsatellite stable (MSS) recurrent/persistent endometrial cancerP.A. Konstantinopoulos,A.A. Gockley,N. Xiong,N. Tayob,C.N. Krasner,M. Buss,S. Campos,S. Schumer,A.A. Wright,J.F. Liu, M. Shea, Y. Oladapo,C. Castro,M.M. Polak,C. Whalen, S. Bouberhan,S.A. Cannistra,R.T. Penson,G. Fleming,U.A. MatulonisAnnals of Oncology（2020）引用 10|浏览66暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
